Information Provided By: 
Fly News Breaks for February 4, 2016
ALXN
Feb 4, 2016 | 07:26 EDT
Brean Capital said the weakness in Alexion following its Q4 results is a buying opportunity. The firm feels the revenue miss was due to foreign exchange headwinds and that its product pipeline will lead to diversification. Brean Capital, which views Alexion as a core biotech holding, reiterated its Buy rating and $221 price target on the shares.
News For ALXN From the Last 2 Days
There are no results for your query ALXN
